Skip to content

To evaluate the therapeutic effect of transcranial direct current stimulation on visual field defect caused by optic atrophy

To evaluate the therapeutic effect of transcranial direct current stimulation on visual field defect caused by optic atrophy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033880
Enrollment
Unknown
Registered
2020-06-15
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optic atrophy

Interventions

Case series:transcranial direct current stimulation

Sponsors

Beijing Tsinghua Changgung hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Normal tention glaucoma patient. 24-hour intraocular pressure measurement, optic nerve fiber layer defect and visual field defect were stable for more than one year. The visual field defect involved the central 3 degree visual field; 2. Non arteritis ischemic optic neuropathy, blood pressure, optic nerve fiber layer defect and visual field defect are stable for more than one year. The visual field defect involved the central 3 degree visual field.

Exclusion criteria

Exclusion criteria: 1. The age is less than 18 years old or more than 80 years old; 2. Patients without informed consent; 3. progressive stroke; transient ischemic attack; 4. The corrected visual acuity was lower than 0.1, the intraocular pressure was not well controlled, the intraocular pressure was more than 18mmhg continuously or the daily curve of intraocular pressure was more than 5mmhg, and the visual field was damaged due to retinopathy; 5. Have serious infection or serious complication (heart, lung, liver, kidney); 6. Patients using implantable electronic devices, such as pacemakers; 7. Patients with metal implants in the brain; 8. Pregnant women; 9. Patients with local skin injury or inflammation; 10. Patients with hyperalgesia in the stimulation area.

Design outcomes

Primary

MeasureTime frame
perimetry;

Countries

China

Contacts

Public ContactLiu Xuan

Beijing Tsinghua Changgung Hospital

liuxuan16@aliyun.com+86 13681521510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026